Safety of Tocilizumab in COVID-19 Patients and Benefit of Single-Dose: The Largest Retrospective Observational Study

Severe acute respiratory coronavirus-2 (SARS-CoV-2) still presents a public threat and puts extra strain on healthcare facilities. Without an effective antiviral drug, all available treatment options are considered supportive. Tocilizumab as a treatment option has to date shown variable results. In...

Descripció completa

Dades bibliogràfiques

Autors principals:	Ayman M. Al-Qaaneh, Fuad H. Al-Ghamdi, Sayed AbdulAzeez, J. Francis Borgio
Format:	Artigo
Idioma:	Inglês
Publicat:	MDPI AG 2022-03-01
Col·lecció:	Pharmaceutics
Matèries:	COVID-19 patient tocilizumab mortality treatment ICU admission monoclonal antibody
Accés en línia:	https://www.mdpi.com/1999-4923/14/3/624
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!